|
EspAddText
EspRemoveText
|
Avoiding negative consequences to health care delivery from federal taxation policy
|
Response to consultation
|
2016
|
|
EspAddText
EspRemoveText
|
Canada's Food Guide
|
Response to consultation
|
2018
|
|
EspAddText
EspRemoveText
|
CMA response to patented medicines regulations consultations
|
Response to consultation
|
2017
|
|
EspAddText
EspRemoveText
|
CMA's Response to Health Canada's Public Consultation Guide to New Authorities in reference to Bill C-17, Protecting Canadians from Unsafe Drugs Act
(Vanessa's Law)
|
Response to consultation
|
2015
|
|
EspAddText
EspRemoveText
|
Consultation on proposed front-of-package labelling
|
Response to consultation
|
2018
|
|
EspAddText
EspRemoveText
|
Consultation on the prescription drug list: Naloxone
|
Response to consultation
|
2016
|
|
EspAddText
EspRemoveText
|
Consultation on the renewal of Federal Tobacco Control Strategy
|
Response to consultation
|
2017
|
|
EspAddText
EspRemoveText
|
Excise duty framework for cannabis products
|
Response to consultation
|
2017
|
|
EspAddText
EspRemoveText
|
Federal Monitoring and Reporting Regime for MAID
|
Response to consultation
|
2017
|
|
EspAddText
EspRemoveText
|
Federal monitoring of medical assistance in dying regulations
|
Response to consultation
|
2018
|
|
EspAddText
EspRemoveText
|
Front-of-package labelling consultation
|
Response to consultation
|
2016
|
|
EspAddText
EspRemoveText
|
Health Canada consultation on Canadian drugs and substances strategy
|
Response to consultation
|
2018
|
|
EspAddText
EspRemoveText
|
Health Canada consultation on edible cannabis, extracts & topicals
|
Response to consultation
|
2019
|
|
EspAddText
EspRemoveText
|
Health Canada consultation on potential market for cannabis health products that would not require practitioner oversight
|
Response to consultation
|
2019
|
|
EspAddText
EspRemoveText
|
Health Canada consultation on proposed vaping products promotion regulations
|
Response to consultation
|
2020
|
|
EspAddText
EspRemoveText
|
Health Canada consultation on reducing youth access and appeal of vaping products
|
Response to consultation
|
2019
|
|
EspAddText
EspRemoveText
|
Health Canada consultation on regulatory amendments regarding tramadol
|
Response to consultation
|
2018
|
|
EspAddText
EspRemoveText
|
Health Canada consultation on restriction of marketing and advertising of opioids
|
Response to consultation
|
2018
|
|
EspAddText
EspRemoveText
|
Health Canada consultation on the impact of vaping products advertising on youth and non-users of tobacco products
|
Response to consultation
|
2019
|
|
EspAddText
EspRemoveText
|
Health Canada consultation on tobacco products regulations (plain and standardized appearance)
|
Response to consultation
|
2018
|